GPCR drug discovery: new agents, targets and indications
G protein-coupled receptors (GPCRs) form one of the largest drug target families, reflecting their involvement in numerous pathophysiological proce…
Category: Drug development
Synthetic lethal strategies for the development of cancer therapeutics
Synthetic lethality is a genetic phenomenon whereby the simultaneous presence of two different genetic alterations impairs cellular viability. Impo…
The journey of the cardiovascular polypill from its conception to the WHO List of Essential Medicines
Cardiovascular disease (CVD) has achieved pandemic proportions and is currently the leading cause of death worldwide. Barriers to optimal secondary…
Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations
The treatment strategy for children and adolescents with chronic myeloid leukemia in the chronic phase (CML-CP) has evolved from allogeneic hematop…
Sinulariapeptide F, a new peptide from culture broth of marine-derived fungus Simplicillium sp. SCSIO 41222
One new compound named sinulariapeptide F (1) together with one known butyrolactone (2) and seven known peptides (3–9…
Cryptoic acids A and B, benzene-containing polyketides, and cyclocryptamide, a modified diketopiperazine, from an actinomycete of the genus Cryptosporangium
Two new benzene-containing polyketides, cryptoic acids A (1) and B (2), along with a new acylated diketopiperazine designated cyclocr…
KRN7000 analogues as biofilm disrupting agents against Streptococcus pyogenes and Proteus mirabilis
In this study, three KRN7000 analogues with variations in the sugar and glycosidic linkage were synthesised to assess their efficacy in disrupting …